Effects of patient-tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low-density lipoprotein cholesterol in patients with type2 diabetes
- Authors
- Son, Jang Won; Kim, Dong Jun; Lee, Chang Beom; Oh, Seungjoon; Song, Kee-Ho; Jung, Chan Hee; Mok, Ji Oh; Kim, Jong Hwa; Moon, Min Kyong; Choi, Kyung Mook; Cho, Jae Hyoung; Choi, Sung Hee; Kim, Soo Kyung; Park, Kang Seo; Kim, Hye Soon; Kim, In Joo; Kim, Young Il; Kim, Hae Jin; Kim, Sang Yong; Kim, Sungrae
- Issue Date
- Sep-2013
- Publisher
- Blackwell Publishing Asia Pty Ltd
- Keywords
- Atorvastatin; Low-density lipoprotein cholesterol; Type2 diabetes mellitus
- Citation
- Journal of Diabetes Investigation, v.4, no.5, pp 466 - 474
- Pages
- 9
- Journal Title
- Journal of Diabetes Investigation
- Volume
- 4
- Number
- 5
- Start Page
- 466
- End Page
- 474
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13412
- DOI
- 10.1111/jdi.12074
- ISSN
- 2040-1116
2040-1124
- Abstract
- Aims/Introduction Recently, patient-tailored statin therapy was proven effective for achieving target low-density lipoprotein (LDL) cholesterol levels. It is unclear, however, whether this therapeutic modality would be effective for atherogenic lipid profiles and inflammation in patients with type2 diabetes. Materials and Methods The present study was an 8-week, multicenter, single-step titration trial of patient-tailored atorvastatin therapy (10, 20 and 40mg) according to baseline LDL cholesterol levels in 440 patients with type2 diabetes. We measured the LDL particle size by polyacrylamide gel electrophoresis, and used high-sensitivity C-reactive protein (hsCRP) and adiponectin as surrogate markers of inflammation. Results In the intention-to-treat analysis, 91% of the patients achieved their LDL cholesterol targets (<2.6mmol/L) at week8. There were significant reductions at week8 in total cholesterol, triglycerides, non-high-density lipoprotein cholesterol (HDL) cholesterol, and the total cholesterol:HDL cholesterol ratio compared with the baseline values for all of the doses. The mean LDL particle size was significantly increased, and the small, dense LDL cholesterol levels were decreased in a dose-dependent manner over the study period. In addition, the hsCRP levels were decreased in those high-risk patients with baseline hsCRP levels over 3mg/L (P<0.001), and the adiponectin levels tended to increase with all of the doses (P=0.004) at 8weeks. Conclusions Patient-tailored atorvastatin therapy based on LDL cholesterol at baseline was effective in ameliorating atherogenic LDL particle size and inflammation, in addition to achieving the target LDL cholesterol level without an undesirable effect on glycemic control in patients with type2 diabetes. This trial was registered with ClinicalTrials.gov (no. NCT01239849).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13412)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.